Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11527 posts found.

Novartis says its psoriasis drug bests Janssen’s in comparison study

March 7, 2016 Research and Development, Sales and Marketing Cosentyx, Novartis, Stelara

Novartis has announced new data from a study comparing its drug Cosentyx to Janssen’s Stelara, which it says demonstrates Cosentyx’s …
News

Baxalta seeks European marketing rights for haemophilia drug

March 3, 2016 Research and Development, Sales and Marketing Adynovi haemophilia a, Baxalta

Baxalta says it has filed for marketing authorisation for its haemophilia drug Adynovi with European regulators. The European Medicines Agency …
News

UCB targets regulatory filing for its osteoporosis drug in 2016

March 3, 2016 Medical Communications, Research and Development, Sales and Marketing Romosozumab, UCB Pharma, osteoporosis

Belgian drug company UCB says it is looking at a regulatory filing for its trial drug romosozumab to treat osteoporosis …
News

Amgen sues Novartis over Enbrel biosimilar

March 3, 2016 Research and Development, Sales and Marketing Amgen, Novartis, Sandoz, biosimilars

Amgen has filed a suit in a US court against Novartis’ generics unit Sandoz, in a bid to protect bestselling …
News

Valeant company group chairman and executive vice president resigns

March 3, 2016 Medical Communications, Sales and Marketing Valeant, appointed, resignation

In an already troubled week for Valeant Pharmaceuticals, the company has now announced that its group chairman and executive vice …
Appointment

Novo says diabetes drug Xultophy cost-effective versus insulin intensification treatment

March 2, 2016 Sales and Marketing Novo Nordisk, Xultophy, diabetes

Novo Nordisk says findings show its Tresiba and Victoza combo Xultophy (insulin degludec/liraglutide: IDegLira), is cost-effective compared to insulin intensification …
News

FDA approves Gilead’s Odefsey for treatment of HIV-1 infection

March 2, 2016 Research and Development, Sales and Marketing Gilead Sciences, HIV, Odefsey

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has approved its TAF-based single tablet regimen Odefsey …
News

Janssen slams NICE decision on Imbruvica

March 2, 2016 Research and Development, Sales and Marketing CLL, Cancer, Cancer Drugs Fund, Janssen, Johnson & Johnson, NICE, imbruvica

Janssen, the R&D arm of pharma major Johnson & Johnson, says it is extremely disappointed following regulator NICE’s announcement that …
News

Top 10 medicines issued in England by prescription cost in 2014-15

March 2, 2016 Research and Development, Sales and Marketing Cost, Humira, NHS, prescription

AbbVie, Humira (adalimumab), £371m. This drug treats a variety of conditions including psoriatic arthritics, Crohn’s disease and ulcerative colitis. The …
Feature

Clinton steps up attacks on Valeant in latest campaign advert

March 2, 2016 Research and Development, Sales and Marketing Hilary Clinton, Valeant

This is not the first time the pharma industry has drawn the ire of the US presidential hopefuls, but Hilary …
News

LEO Pharma UK/Ireland appoints new dermatology director

March 2, 2016 Medical Communications, Sales and Marketing

LEO Pharma has appointed Michael Hinchy as dermatology director with responsibility for its UK/Ireland affiliate. Michael brings over 16 years …
Appointment

Merck begins late-stage trials of Humira biosimilar

March 2, 2016 Research and Development, Sales and Marketing AbbVie, Humira, Merck, biosimilars

Merck has announced the beginning of a global phase III study of its Humira (adalimumb) biosimilar, MSB11022, in chronic plaque …
News

Exelixis signs $200 million licensing deal for cancer drug

March 1, 2016 Research and Development, Sales and Marketing Cancer, Cometriq, Exelixis, ipsen

Exelixis has signed a licensing agreement with French biotech firm Ipsen for its cancer drug Cometriq (cabozantinib) for an upfront …
News

Two Celgene cancer drugs approved in Ireland

March 1, 2016 Research and Development, Sales and Marketing Abraxane, Cancer, Celgene, Revlimid, imnovid

Irish regulators have recommended two cancer treatments from Celgene: Imnovid (pomalidomide), in combination with dexamethasone, for previously-treated relapsed and refractory …
News

Delivering successful new drugs

March 1, 2016 Manufacturing and Production, Sales and Marketing AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, patents, pharma

Pharma companies are struggling with challenges specific to their industry. Patents for many drugs, that had created massive amounts of …
Feature
The Gateway to Local Adoption Series

Latest content

Scots neonatal innovations target hearing loss and earlier care

August 28, 2026

FDA grants De Novo authorisation to light-filtering device for migraine

August 28, 2026

Southgate opens Innovation Lab for logistics and fulfilment development

August 27, 2026

Bioptimus partners with Cancer Research Horizons to expand AI cancer data set

August 27, 2026

Agentis Health Group acquires Clinical Pharmacist Solutions

August 26, 2026